FDA Approves Mavacamten under Brand Name Camzyos Published on May 8, 2022July 4, 2022 by hcmbeat2 Comments At long last, there is a FDA approved drug specifically intended for the treatment of hypertrophic cardiomyopathy. After several years of testing, and based on the results of the groundbreaking EXPLORER-HCM trial, Bristol Myers Squibb’s new drug mavacamten, being marketed under the brand name Camzyos, is now available to HCM patients. Continue reading “FDA Approves Mavacamten under Brand Name Camzyos” → Share this: Share on Facebook (Opens in new window) Facebook Share on X (Opens in new window) X Email a link to a friend (Opens in new window) Email Share on LinkedIn (Opens in new window) LinkedIn Share on Pinterest (Opens in new window) Pinterest More Print (Opens in new window) Print Like Loading...
HCM Beat 